Industry ShowcaseA Focused Approach: Targeting Muscarinic Receptors in SchizophreniaSupported by Karuna Therapeutics

Registration Options

Activity Date: 04/08/2024

Session Time and Location

The live session is complete.

Session Summary

Currently approved drugs for schizophrenia have proven useful; however, unmet medical needs still exist for this patient population. This program will shed light on possible mechanisms for an innovative class of therapeutics that have shown promise in schizophrenia by targeting muscarinic acetylcholine receptors in the brain.

Learning Objectives

Review the potential involvement of, and rationale for, targeting muscarinic receptors in schizophrenia.
Introduce muscarinic agonists currently under investigation for the treatment of symptoms of schizophrenia.

Faculty Information

José Rey, MS, PharmD, BCPP

View biographical information

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

The bookmark/discussion system is temporarily disabled. Please check back later.

Grant Support

Supported by Karuna, a Bristol Myers Squibb Company